how big is Medplus Health?

As of Jun 06, Medplus Health Services Ltd has a market capitalization of 10,929.00 Cr, with recent net sales of 6,136.06 Cr and a net profit of 150.33 Cr for the latest four quarters. Shareholder's funds are 1,577.93 Cr, and total assets amount to 2,919.81 Cr.

Market Cap: <BR>As of Jun 06, Medplus Health Services Ltd has a market capitalization of 10,929.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: <BR>For the latest 4 quarters, Medplus Health reported a sum of Net Sales of 6,136.06 Cr and a sum of Net Profit of 150.33 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: <BR>This is Consolidated data for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 1,577.93 Cr, while Total Assets amount to 2,919.81 Cr.

What does Medplus Health do?

MedPlus Health Services Ltd is a mid-cap retail company specializing in health services, incorporated in 2006 and transitioned to a public company in 2021. As of March 2025, it reported net sales of ₹1,510 Cr and a net profit of ₹51 Cr, with a market cap of ₹10,941 Cr.

Overview: <BR>MedPlus Health Services Ltd operates in the retailing industry as a mid-cap company.<BR><BR>History: <BR>The company was incorporated in 2006 as 'MedPlus Health Services Private Limited' in Hyderabad. It transitioned to a Public Limited Company on 1 June 2021, and the name was changed to MedPlus Health Services Limited on 28 June 2021. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 1,510 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 51 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 10,941 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 72.00 <BR>Industry P/E: 99 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.43 <BR>Return on Equity: 8.64% <BR>Price to Book: 6.26 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Who are in the management team of Medplus Health?

As of March 2023, the management team of Medplus Health includes GANGADI MADHUKAR REDDY (Chairman, Managing Director & CEO), Anish Saraf (Director), Atul Gupta (Nominee), and several Independent Directors: Murali Sivaraman, Madhavan Ganesan, and Hiroo Mirchandani, along with Manoj Kumar Srivastava (Company Secretary & Compliance Officer). They oversee the company's operations and strategic direction.

As of March 2023, the management team of Medplus Health includes the following individuals:<BR><BR>1. GANGADI MADHUKAR REDDY - Chairman, Managing Director & CEO<BR>2. Anish Saraf - Director<BR>3. Atul Gupta - Nominee<BR>4. Murali Sivaraman - Independent Director<BR>5. Madhavan Ganesan - Independent Director<BR>6. Hiroo Mirchandani - Independent Director<BR>7. Manoj Kumar Srivastava - Company Secretary & Compliance Officer<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

When is the next results date for Medplus Health?

No Upcoming Board Meetings

Has Medplus Health declared dividend?

No Dividend History Available

Who are the peers of the Medplus Health?

Medplus Health's peers include Entero Healthcare, Khemani Distribution, M K Exim India, and others. In terms of management risk, Medplus Health has a below-average rating, with a 1-year return of 29.19%, lower than Khemani Distribution's 73.21% but higher than M K Exim India's -8.86%.

Peers: The peers of Medplus Health are Entero Healthcar, Khemani Distrib., M K Exim India, MRP Agro, Osia Hyper Reta., Purple United, Purv Flexi, Silgo Retail, and Magson Retail.<BR><BR>Quality Snapshot: Excellent management risk is observed at Khemani Distrib., MRP Agro, Osia Hyper Reta., Purple United, and Magson Retail, while Average management risk is found at Entero Healthcar and M K Exim India. Below Average management risk is noted for Medplus Health, Purv Flexi, and Silgo Retail. In terms of growth, Excellent growth is seen at Entero Healthcar, Osia Hyper Reta., and Purple United, while Good growth is observed at Medplus Health, M K Exim India, and MRP Agro. Average growth is reported for Khemani Distrib., and Below Average growth is noted for Purv Flexi and Silgo Retail. Capital Structure ratings show Excellent at Khemani Distrib. and M K Exim India, Good at Entero Healthcar and MRP Agro, while Below Average is seen at Medplus Health, Osia Hyper Reta., Purple United, Purv Flexi, and Silgo Retail.<BR><BR>Return Snapshot: Khemani Distrib. has the highest 1-year return at 73.21%, while M K Exim India has the lowest at -8.86%. Medplus Health's 1-year return is 29.19%, which is higher than M K Exim India but lower than Khemani Distrib. Additionally, M K Exim India, MRP Agro, and Silgo Retail have negative six-month returns.

Who are the top shareholders of the Medplus Health?

The top shareholders of Medplus Health include promoters with 59.34% pledged holdings, led by Lone Furrow Investments Private Limited at 14.44%. Mutual funds hold 21.59%, foreign institutional investors 15.61%, and individual investors account for 13.1%.

The top shareholders of Medplus Health include a mix of promoters, mutual funds, and foreign institutional investors (FIIs). The majority shareholders are the promoters, with a significant portion of their holdings pledged at 59.34%. <BR><BR>The promoter with the highest holding is Lone Furrow Investments Private Limited, which owns 14.44% of the company. Mutual funds collectively hold 21.59% of the shares through 17 different schemes, while FIIs hold 15.61% through 147 different investors. The highest public shareholder is Nippon Life India Trustee Ltd, which holds 7.58%. Additionally, individual investors account for 13.1% of the total shareholding.

Are Medplus Health latest results good or bad?

MedPlus Health's latest Q2 FY26 results are generally positive, with a 43.26% year-over-year increase in net profit and improved operating margins. However, the revenue growth rate of 6.54% shows a slowdown compared to previous years, raising concerns about future sustainability.

MedPlus Health's latest results for Q2 FY26 indicate a generally positive performance, despite some challenges. The company reported a net profit of ₹55.50 crores, which is a significant increase of 43.26% year-over-year and a 31.02% increase from the previous quarter. This growth in profit is supported by a revenue increase of 6.54% year-over-year, reaching ₹1,679.33 crores, and an impressive sequential revenue growth of 8.86%.<BR><BR>Moreover, the operating margin improved to 8.86%, marking a 96 basis points increase compared to the same quarter last year, reflecting enhanced operational efficiency. The net profit margin also rose to 3.30%, up from 2.46% in the previous year.<BR><BR>However, while these results demonstrate strong profitability and margin expansion, there are concerns regarding the company's growth trajectory. The revenue growth rate of 6.54% is a deceleration compared to historical double-digit growth rates, which raises questions about the sustainability of this growth moving forward.<BR><BR>Additionally, the stock has faced volatility, currently trading lower than its 52-week high, which may reflect investor caution despite the improving fundamentals. Overall, while the results show positive trends in profitability and margins, the slowdown in revenue growth and broader market conditions warrant a cautious outlook.

Is Medplus Health overvalued or undervalued?

As of November 3, 2025, Medplus Health is considered attractive but overvalued due to a high PE ratio of 49.98 and low profitability metrics, despite a strong recent stock performance.

As of 3 November 2025, the valuation grade for Medplus Health has moved from very attractive to attractive. The company is currently considered overvalued based on its high PE ratio of 49.98 and an EV to EBITDA ratio of 13.80, which are significantly higher than its peers. For instance, Avenue Supermarts and Trent have PE ratios of 98.98 and 105.78, respectively, indicating that Medplus Health, while attractive, is still trading at a premium compared to its competitors.<BR><BR>In terms of key financial metrics, Medplus Health has a Price to Book Value of 0.53 and a PEG Ratio of 0.53, suggesting some growth potential relative to its price. However, the low ROCE of 1.77% and ROE of 1.06% raise concerns about profitability and efficiency. Despite a recent strong performance with a 1-year stock return of 19.68% compared to the Sensex's 5.34%, the overall valuation suggests that Medplus Health may be overvalued in the current market environment.

Is Medplus Health technically bullish or bearish?

As of November 24, 2025, the market trend is mildly bearish, indicated by bearish signals from the weekly MACD and KST, mixed Bollinger Bands, and no momentum from the RSI, suggesting a cautious approach as the stock remains below its 52-week high.

As of 24 November 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD and KST both indicating bearish signals, while the daily moving averages also reflect a mildly bearish outlook. The Bollinger Bands show a mixed signal with a mildly bearish stance on the weekly and bullish on the monthly. The Dow Theory indicates no trend on the weekly and mildly bearish on the monthly, contributing to the overall bearish sentiment. The RSI shows no signals in both weekly and monthly timeframes, indicating a lack of momentum. Overall, the indicators suggest a cautious approach as the stock remains below its 52-week high.

How has been the historical performance of Medplus Health?

Medplus Health has shown consistent growth in net sales and profitability, with net sales increasing from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025, and profit after tax rising from INR 1.79 crore to INR 150.23 crore during the same period. The company's total assets and cash flow from operating activities have also significantly improved.

Answer:<BR>The historical performance of Medplus Health shows a consistent growth trajectory in net sales and profitability over the past several years.<BR><BR>Breakdown:<BR>Medplus Health's net sales have steadily increased from INR 2,870.60 crore in March 2020 to INR 6,136.05 crore in March 2025. This growth is reflected in the total operating income, which rose from INR 2,870.60 crore to INR 6,136.05 crore during the same period. The company's total expenditure, excluding depreciation, also grew, reaching INR 5,648.95 crore in March 2025, up from INR 2,736.92 crore in March 2020. Operating profit (PBDIT) has shown a significant increase, rising from INR 150.96 crore in March 2020 to INR 535.72 crore in March 2025. The profit before tax has also improved, moving from INR 29.36 crore in March 2020 to INR 183.29 crore in March 2025, while profit after tax increased from INR 1.79 crore to INR 150.23 crore in the same timeframe. The company's total assets have grown from INR 1,308.54 crore in March 2020 to INR 3,260.27 crore in March 2025, and total liabilities have increased from INR 1,308.54 crore to INR 3,260.27 crore. Cash flow from operating activities has improved significantly, reaching INR 540 crore in March 2025, compared to INR -6 crore in March 2020. Overall, Medplus Health has demonstrated robust growth in sales, profits, and asset base over the years.

Why is Medplus Health falling/rising?

As of 16-Dec, Medplus Health Services Ltd's stock price is at 800.70, reflecting a decline of 7.5 (-0.93%). The stock has underperformed against the Sensex and shows weak long-term fundamentals, with a significant year-to-date decline and concerning debt servicing capabilities.

As of 16-Dec, Medplus Health Services Ltd's stock price is falling, currently at 800.70, reflecting a decrease of 7.5 (-0.93%). This decline can be attributed to several factors. Firstly, the stock has underperformed against the benchmark Sensex, with a performance of -1.45% over the past week compared to a slight increase of +0.02% for the index. Additionally, the stock has shown a significant year-to-date decline of -4.05%, while the Sensex has gained 8.37% during the same period.<BR><BR>Despite some positive indicators, such as the company declaring positive results for the last five consecutive quarters and a notable increase in operating profit, the overall long-term fundamentals appear weak. The average Return on Equity (ROE) stands at only 5.80%, and the company's ability to service its debt is concerning, as indicated by a poor EBIT to Interest ratio of 1.92. Furthermore, a substantial 59.34% of promoter shares are pledged, which can exert additional downward pressure on the stock in a falling market.<BR><BR>The stock's performance today has also been disappointing, underperforming its sector by -1.7%. Although there has been a rise in investor participation, with delivery volume increasing by 90.69% against the 5-day average, the overall trend remains negative, particularly when considering the stock's consistent underperformance against benchmarks over the last three years.

Should I buy, sell or hold Medplus Health?

Which are the latest news on Medplus Health?